Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants
      QxMD      Google Scholar   
Citation:
Med Care vol 46 (3) 303-308
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
681  
Children:
None
Program:
CCP
Primary Committee:
Health Outcomes
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, CA33601, U10 CA035091, U10 CA052784, U10 CA071323, U10 CA077658, CA47577, CA32291, N01 CA032102, U10 CA045564, CA41287, U10 CA035279, U10 CA045808, U10 CA031946, U10 CA033601, U10 CA045389, CA60138, U10 CA077597, U10 CA035421, U10 CA045418, U10 CA077440, U10 CA041287, U10 CA032102, U10 CA035113, U10 CA047559, CA93892, U10 CA023318, U10 CA074811, K07 CA093892, U10 CA025224, U10 CA047642, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
               
Networks:
 
Study
CALGB-70101
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
N/A
Keywords:
elderly, chemotherapy, Medicare, validation, toxicity, cancer